Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials
Martina L. Porter, Antonio Martorell, Christopher J. Sayed, Falk G. Bechara, Hadar Lev-Tov, Jennifer L. Hsiao, John W. Frew, Ziad Reguiaï, Melinda J. Gooderham, Noah Goldfarb, Hessel H. van der Zee, Veronique del Marmol, Angelo V. Marzano, Benjamin D. Ehst, Lindsay S. Ackerman, Koremasa Hayama, Chenwei Tian, Jennifer Kelley, Huiling Zhen, Joslyn S. Kirby, Kurt Brown, Leandro L. Santos, Christos C. Zouboulis · 2026
Read Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials by Martina L. Porter, Antonio Martorell, Christopher J. Sayed, Falk G. Bechara, Hadar Lev-Tov, Jennifer L. Hsiao, John W. Frew, Ziad Reguiaï, Melinda J. Gooderham, Noah Goldfarb, Hessel H. van der Zee, Veronique del Marmol, Angelo V. Marzano, Benjamin D. Ehst, Lindsay S. Ackerman, Koremasa Hayama, Chenwei Tian, Jennifer Kelley, Huiling Zhen, Joslyn S. Kirby, Kurt Brown, Leandro L. Santos, Christos C. Zouboulis (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13473019.txt.
Description
Martina L. Porter leads two large 2026 trials of a daily pill for a painful skin disease called hidradenitis suppurativa. The disease causes deep lumps and tunnels, often under the arms or in the groin. Each trial enrolled more than six hundred adults with moderate to severe disease. People took one of two doses of povorcitinib, a drug that blocks a key immune signal, or a placebo for the first weeks.
At twelve weeks, about four in ten people on either dose reached the main goal of halving lump counts with no new abscess growth. That rate beat the placebo rate of about three in ten in both trials. Serious side effects stayed rare through the first year. The results give doctors a new oral option to weigh for this hard-to-treat disease.
Catalog record
| CREATOR | Martina L. Porter, Antonio Martorell, Christopher J. Sayed, Falk G. Bechara, Hadar Lev-Tov, Jennifer L. Hsiao, John W. Frew, Ziad Reguiaï, Melinda J. Gooderham, Noah Goldfarb, Hessel H. van der Zee, Veronique del Marmol, Angelo V. Marzano, Benjamin D. Ehst, Lindsay S. Ackerman, Koremasa Hayama, Chenwei Tian, Jennifer Kelley, Huiling Zhen, Joslyn S. Kirby, Kurt Brown, Leandro L. Santos, Christos C. Zouboulis |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 105255 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |